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Aims In a nationwide cohort of primary (PP-ICD) and secondary prevention (SP-ICD) implantable cardioverter defibrillator
(ICD) patients, we aimed to investigate the association between co-morbidity burden and risk of appropriate ICD
therapy and mortality.
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Methods
and results
We identified all patients >18 years, implanted with first-time PP-ICD (n = 1873) or SP-ICD (n = 2461) in Denmark
from 2007 to 2012. Co-morbidity was identified in administrative registers of hospitalization and drug prescription
from pharmacies. Co-morbidity burden was defined as the number of pre-existing non-ICD indication-related
co-morbidities including atrial fibrillation, diabetes, chronic obstructive pulmonary disease, chronic renal disease,
liver disease, cancer, chronic psychiatric disease, and peripheral and/or cerebrovascular disease, and divided into
four groups (co-morbidity burden 0, 1, 2, and ≥3). Through Cox models, we assessed the impact of co-morbidity
burden on appropriate ICD therapy and mortality. Increasing co-morbidity burden was not associated with increased
risk of appropriate therapy, irrespective of implant indication [all hazard ratios (HRs) 1.0–1.4, P = NS]. Using no
co-morbidities as reference, increasing co-morbidity burden was associated with increased mortality risk in PP-ICD
patients (co-morbidity burden 1, HR 2.1; comorbidity burden 2, HR 3.7; co-morbidity burden ≥3, HR 6.6) (all P <
0.001) and SP-ICD patients (co-morbidity burden 1, HR 2.2; co-morbidity burden 2, HR 3.8; co-morbidity burden ≥3,
HR 5.8). With increasing co-morbidity burden, an increasing frequency of patients died without having utilized their
device, with 72% PP-ICD and 45% SP-ICD patients with co-morbidity burden ≥3 dying without prior appropriate
ICD therapy.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Conclusion Increasing co-morbidity burden was not associated with increased risk of appropriate ICD therapy. With increasing
co-morbidity burden, mortality increased, and a higher proportion of patients died, without ever having utilized their
device.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Introduction
The survival benefit of implantable cardioverter defibrillator (ICD)
implantation in patients who have survived a cardiac arrest or
an episode of sustained ventricular tachycardia (VT) was demon-
strated in major clinical trials in the late 1990s.1,2 Since then, the
indications for ICD implantation have evolved to include primary
prevention of sudden cardiac death (SCD), with large randomized
clinical trials showing a significant survival benefit in patients with
depressed LV function, without prior resuscitated cardiac arrest or
a sustained VT episode.2–6
Pharmacological advancements and improved treatment for
myocardial infarction and heart failure have resulted in an increasing
incidence of patients who fulfil the criteria for primary prevention
ICD implantation. Furthermore, the implementation and increasing
use of automatic external defibrillators for out-of-hospital cardiac
arrest has led to a higher survival rate from SCD, and thus an
increasing number of patients who would benefit from a secondary
prevention ICD.7,8
Even though randomized trials are essential for proof-of-concept
and clinical implementation, these trials often have strict inclusion
criteria and thus represent a selected patient population that
might not be representative for ‘real-life’ ICD patients. In order
to assess the prognosis in ICD patients in the setting of multiple
co-morbidities, it is important to look beyond the results from
landmark trials, with data from large, prospective, clinical registries.
In a nationwide Danish cohort of consecutively implanted
ICD recipients, we aimed to investigate the association between
increasing number of non-ICD indication-related co-morbidities
and the risk of appropriate ICD therapy and all-cause mortality
in primary and secondary prevention ICD patients, respectively.
Methods
Registries
Demographic information on date of birth, gender and date of death
is registered in the Danish Civil Person Register.9–11
The Danish Pacemaker and ICD Register (DPIR)
This registry contains prospectively collected data on all pacemaker and
ICD implantations performed in Denmark, with information on implant
indication, symptomology, and device and lead type at the time of
device implantation.12,13 Since 1 January 2007, information on NYHA
class and LVEF has been documented at the time of implantation, and
follow-up data on ICD therapy have been prospectively recorded.13
The Danish National Patient Register
This contains data on all outpatient visits, hospital admissions, and oper-
ative procedures in Denmark since 1978.14 Each patient contact is
coded with one primary and up to several secondary diagnoses accord-
ing to ICD-8 (International Classification of Diseases, 8th revision) until
1993 and ICD-10 (10th revision) from 1994 onwards. These admission
codes are used to reimburse the hospitals for expenses associated with
hospital contacts and procedures performed. As a result, the accuracy
of the registry is high. ..
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.. The Danish Register for Medicinal Products Statistics
This contains individual-level information on all redeemed prescrip-
tions fromDanish pharmacies from 1995, with information on type and
name of the drug, according to the Anatomical Therapeutic Chemical
(ATC) classification, as well as the date, dose, and quantity dispensed.15
All Danish residents are assigned an individual and permanent civil
person registration number at birth or when moving to the country,9,10
enabling cross-linkage of data from the above-mentioned registries.
Study population
We performed a population-based cohort study including all Danish
patients with a first-time ICD implantation with a primary or secondary
prevention indication in the period 1 January 2007 to 31 December
2012 (n= 4547). Patients with a CRT-D were not included. Exclusion
criteria included, missing indication for implant (n=114), age <18
years (n= 40), a non-valid date of birth (n= 43), and emigration prior
to implantation (n=16), leaving us with 4334 patients. Follow-up was
conducted from time of device implantation until 31 December 2012.
Patient characteristics,
pharmacotherapy, and co-morbidities
Pharmacotherapy at implant was defined as a redeemed prescription
within 180 days prior to implant or 7 days after implant.
Co-morbidities prior to device implantation were determined
using diagnoses and procedural codes from The Danish National
Patient Register, as well as ATC codes for redeemed prescriptions
from the Danish National Register for Medicinal Products Statistics,
as described previously16–22 (Supplementary material online, Table
S1). For the current study, we investigated the risk of pre-existing
non-ICD indication-related co-morbidities and associated outcome.
Non-ICD indication-related co-morbidities were defined as atrial fibril-
lation (AF), diabetes, chronic obstructive pulmonary disease (COPD),
chronic renal disease, peripheral vascular disease, cerebrovascular
disease, cancer, liver disease, and chronic psychiatric disease. One
point was assigned for each pre-existing non-ICD indication-related
co-morbidity, creating a cumulated co-morbidity burden. This method-
ology has been used previously.23
Endpoints
Information regarding appropriate ICD therapy was obtained from the
DPIR, and defined as anti-tachycardia pacing (ATP) or shock rendered
for VT or ventricular fibrillation (VF) as evaluated by the treating
physician. Death and time of death were identified through the Danish
Civil Person Register.
Ethics
Retrospective register-based studies do not need ethical approval
in Denmark. Permission to use data from the Danish Registries
was granted by The Danish Data Protection Agency (2007-58-0015,
internal reference: GEH-2014-015).
Statistics
Clinical characteristics were compared between secondary and
primary prevention ICD patients using the Kruskal–Wallis test
© 2016 The Authors
European Journal of Heart Failure © 2016 European Society of Cardiology
ICD implantation and co-morbidities 379
for continuous variables, and 𝜒2 test or Fisher’s exact test for
dichotomous variables where appropriate.
Temporal development in co-morbidity burden at implant was tested
for significance using the Cochran–Armitage test for trend.
To investigate device utilization, we identified a subset of patients
who either had experienced an appropriate ICD therapy (i.e. patients
who gained benefit from the device) or died without ever having
utilized their device appropriately (i.e. patients who did not gain benefit
from the device) and plotted these percentages in a bar chart by
co-morbidity burden and implant indication. Patients who were still
alive and never had experienced an appropriate ICD therapy were
excluded from this analysis.
Absolute risk over time for the endpoints are illustrated by
Kaplan–Meier plots for the endpoint of death, with differences
between groups calculated by the –2Log likelihood ratio test. For
the endpoint of appropriate therapy, cumulative incidence curves were
plotted in order to account for competing risk of death. Multivariate
Cox proportional hazards models were applied to assess the influence
of non-ICD indication-related co-morbidities on death and appropriate
therapy, adjusting for age and sex.
Hazard ratios (HRs), their 95% confidence intervals (CIs), and
affiliated P-value are reported. A two-tailed P-value below 0.05 was
considered significant.
All statistical analyses were conducted through the secure servers
of Statistics Denmark, using SAS 9.4 statistical software (SAS Institute
Inc., Cary, NC, USA).
Results
Clinical characteristics of primary
and secondary prevention implantable
cardioverter defibrillator patients
Patients with an ICD were predominantly male (80%). Primary
prevention ICD patients presented with more advanced cardiac
disease and received more heart failure medication, as com-
pared with secondary prevention ICD patients. However, no dif-
ference was evident in age at implant or co-morbidity burden
(Table 1). In primary prevention ICD patients, we observed a tem-
poral increase in age at implant (2007, 59.4± 13.7 years; 2012,
62.6± 12.3 years, P< 0.009), as well as in the burden of non-ICD
indication-related co-morbidities at implant, with reductions in
the percentage of patients without non-ICD indication-related
co-morbidities (2007, 49%; 2012, 41%, P for trend= 0.028), and
an increase in the percentage of patients with ≥2 non-ICD
indication-related co-morbidities (2007, 16%; 2012, 25%, P for
trend= 0.002). Age at implant and co-morbidity burden remained
stable over time in secondary prevention ICD patients (P for
trend= 0.105–0.768).
Co-morbidity burden and appropriate
implantable cardioverter defibrillator
therapy
Over a mean follow-up of 2.52±1.65 years, 1057 (24%) patients
experienced appropriate ICD therapy, with 290 (15%) of pri-
mary and 767 (31%) of secondary prevention patients (P< 0.001), ..
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Table 1 Clinical characteristics at the time of
implantation
Clinical characteristics Primary
(n= 1873)
Secondary
(n= 2461)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age (years) 62.2±12.2 62.3±13.2
Male gender 1514 (81) 1949 (79)
LVEF (%) 29.4±12.4 40.4±14.5*
NYHA class> II 402 (23) 212 (10)*
QRS duration (ms) 103.4± 23.7 102.2± 28.8*
Indication for implantation
Primary prevention 1873 (100) –
Resuscitated cardiac arrest 1097 (45)
Documented spontaneous VT or
syncope with inducible VT/VF
1329 (54)
Other/unknown 35(1)
Co-morbidities
Congestive heart failure 1706 (91) 1483 (60)*
Ischaemic cardiomyopathy 1508 (81) 1743 (71)*
Previous myocardial infarction 1191(64) 1323 (54)*
Previous atrial fibrillation 403 (22) 579 (24)
Diabetes 369 (20) 399 (16)*
Chronic obstructive pulmonary
disease
291 (16) 330 (13)*
Cerebrovascular disease 226 (12) 324 (13)
Peripheral vascular disease 157 (8) 203 (8)
Chronic renal disease 65 (4) 67 (3)
Liver disease 8 (0.4) 22 (0.9)
Cancer 76 (4) 134(5)*
Chronic psychiatric disease 32 (2) 47(2)
Non-ICD indication-related
co-morbidity burdena
No co-morbidities 812 (43) 1113 (45)
Co-morbidity burden=1 660 (35) 800 (33)
Co-morbidity burden= 2 272 (15) 384 (16)
Co-morbidity burden ≥3 129 (7) 164 (7)
Baseline pharmacotherapy
Beta-blocker 1614 (86) 1997 (81)*
ACE inhibitor/ARB 1603 (86) 1682 (68)*
Diuretics 1315 (70) 1256 (51)*
Digoxin 243 (13) 238 (10)*
Amiodarone 111 (6) 420 (17)*
ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction;
NYHA, New York Heart Association; VF, ventricular fibrillation; VT, ventricular
tachycardia.
*P< 0.05:
aNon-ICD indication-related co-morbidity burden: 1 point given for each of
the following co-morbidities: atrial fibrillation, diabetes, chronic obstructive pul-
monary disease, chronic renal disease, peripheral vascular disease, cerebrovas-
cular disease, cancer, liver disease, and chronic psychiatric disease.
irrespective of co-morbidity burden (P= 0.478 for primary and
P= 0.503 for secondary).
The 4-year cumulative incidence for overall appropriate ICD
therapy (ATP or shock) and specifically appropriate shock was
23% and 12%, respectively, for primary prevention patients, and
somewhat higher for secondary prevention patients, with 39% and
21%, respectively (Figure 1A and B). In multivariate Cox regression
© 2016 The Authors
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A B
C D
Figure 1 Cumulative incidence of appropriate implantable cardioverter defibrillator (ICD) therapy in primary (A) and secondary prevention
(B) ICD patients by increasing co-morbidity burden. The probability of death by Kaplan–Meier plots in primary (C) and secondary (D) prevention
ICD patients by increasing co-morbidity burden. Co-morbidity burden was calculated for each patient as a score, giving 1 point for each of the
following non-ICD indication-related co-morbidities present at the time of implant: atrial fibrillation, diabetes, chronic obstructive pulmonary
disease, chronic renal disease, peripheral vascular disease, cerebrovascular disease, cancer, liver disease, and chronic psychiatric disease; no
co-morbidities (black), one co-morbidity (red), two co-morbidities (green), and three or more co-morbidities (blue).
analyses, this risk difference translated into an ∼2-fold increased
risk of appropriate ICD therapy (ATP or shock) in secondary,
as compared with primary prevention patients (HR 2.1, 95% CI
1.86–2.44, P< 0.001), which was irrespective of co-morbidity
burden (P for interaction= 0.653).
Neither primary nor secondary prevention patients with a high
co-morbidity burden experienced more appropriate ICD ther-
apy over time, as compared with patients with no co-morbidities
(Figure 1A and B). In multivariate analyses, we found no association
between increasing co-morbidity burden and the risk of appropri-
ate therapy, regardless of implant indication (Figure 2A).
Analysing the co-morbidities individually, the risk of appropriate
ICD therapy in secondary prevention ICD patients was significantly
increased in patients who presented with prior AF and/or chronic
renal disease (Figure 3A). In primary prevention ICD patients, prior
AF was the only individual co-morbidity significantly associated
with increased risk of appropriate therapy (Figure 3A). .
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. All-cause mortality and co-morbidity
burden
Increasing co-morbidity burden was associated with increased risk
of death, irrespective of implant indication (Figures 1C and D, and
2B).
Primary and secondary prevention patients had similar 4-year
cumulative risk of death of 7% in patients without any non-ICD
indication-related co-morbidities, 19% in patients with one
co-morbidity, 35–36% in patients with two co-morbidities, and
52% in patients with three or more co-morbidities (Figure 1C and
D).
In a subgroup analysis, looking at patients who either experi-
enced an appropriate ICD therapy or died, patients with a high
co-morbidity burden more often died without ever having utilized
their ICD device (Figure 4).
Atrial fibrillation, diabetes, COPD, chronic renal disease, and
peripheral vascular disease were independently associated with
© 2016 The Authors
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Figure 2 Forest plot depicting the association between increasing co-morbidity burden and the risk of appropriate implantable cardioverter
defibrillator (ICD) therapy (A) and all-cause mortality (B) in patients with the same implant indication, always using patients with no
co-morbidities as a reference. Non-ICD indication co-morbidity burden was calculated as a score, giving 1 point for each of the
following co-morbidities: atrial fibrillation, diabetes, chronic obstructive pulmonary disease, chronic renal disease, peripheral vascular disease,
cerebrovascular disease, cancer, liver disease, and chronic psychiatric disease. Multivariate Cox proportional hazards models were used to
assess the risk of the endpoints by increasing non-ICD indication-related co-morbidity burden, adjusting for age and gender. CI, confidence
interval; N/A, not applicable.
© 2016 The Authors
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A
B
Figure 3 Forest plot depicting the risk of appropriate implantable cardioverter defibrillator (ICD) therapy (A) and all-cause mortality (B)
in the presence of different non-ICD indication-related co-morbidities. Individual multivariate Cox models were fitted for each co-morbid
condition and adjusted for age and gender. Not having the specific co-morbidity was used as a reference. CI, confidence interval; py, patient
years.
© 2016 The Authors
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Figure 4 Device utilization. Percentage distribution of patients who either experienced appropriate implantable cardioverter defibrillator
(ICD) therapy (blue) or died without ever experiencing appropriate ICD therapy (black) by increasing co-morbidity burden and implant
indication.
increased risk of death in both primary and secondary prevention
ICD patients (Figure 3B). Cancer, cerebrovascular disease, and
chronic psychiatric disease were only found to be significantly
associated with increased risk of death in secondary prevention
patients (Figure 3B).
Discussion
In a Danish nationwide study of 4334 ICD patients, consecutively
implanted between 2007 and 2012, we found a temporal increase
in age at implant and in frequency of non-ICD indication-related
co-morbid conditions in patients selected for primary prevention
ICD implantation, while this was not the case for patients receiving
an ICD for secondary prevention. Increasing co-morbidity bur-
den was not associated with increased risk of appropriate ICD
therapy. However, with increasing co-morbidity burden, mortality
increased, and a higher proportion of patients died without ever
having utilized their device.
The implantation rate of ICD devices has increased worldwide,
and, in recent years, Denmark has had one of the highest annual
implantation rates among the European countries, reaching 231
implantations per 1 million inhabitants in 2013.24,25 In a recent
study from Denmark, Schmidt et al. reported a five-fold increase in
implantations from 2000 to 2012, with a particular increase in the
elderly and in patients with a high co-morbidity burden.25 These
patients were not well represented in the randomized trials that
provide the foundation for current ICD implantation guidelines.
Therefore, it is important to obtain further knowledge regarding
the prognosis in these patients, and investigate whether they will
derive benefit from ICD implantation, in particular for primary
prevention implantation.
In the current study, we observed an association between
increasing co-morbidity burden and increasing mortality risk, with
a >50% mortality risk at 4 years in patients with co-morbidity bur-
den ≥3. Similar results were found in other studies.25–27 Recently, .
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. Schmidt et al. found a five-fold relative risk increase in mortality
from low to high co-morbidity burden, which is consistent with
our data.25 However, in reporting co-morbidity burden, Schmidt
et al. found that 42% of primary and 29% of secondary prevention
patients had a high burden of co-morbidities, while we only report
7%. The explanation for this discrepancy is in the definition of
co-morbidity burden. Schmidt et al. used Charlson’s co-morbidity
index, which includes ICD indication-related co-morbidities, such
as myocardial infarction and congestive heart failure, while we
only included non-ICD indication-related co-morbidities. Risk
stratifying studies have previously identified several non-cardiac
co-morbidities as risk factors for mortality; however, there was no
specific focus on non-ICD indication-related co-morbidities in the
studies, most patients were enrolled in early years (1997–2008),
and none of the studies included information on appropriate ICD
therapy, making comparisons with our results challenging.27
Interestingly, we found that, with increasing co-morbidity bur-
den, there was an increasing frequency of patients who never
experienced appropriate ICD therapy prior to death, with 72%
of primary and 45% of secondary prevention patients with a high
co-morbidity burden who never had any appropriate utilization of
their ICD device prior to death. Correspondingly, we found no
association between increasing co-morbidity burden and increas-
ing risk of appropriate therapy. There was even a hint that pri-
mary prevention patients with a high co-morbidity burden had a
lower utilization of their device, possibly due to the high mortal-
ity observed in these patients. This raises the question of whether
patients with a high co-morbidity burden gain benefit from ICD
implantation, or if the mortality risk for competing causes is so high
that these patients do not live long enough for the device to exert
its benefit. In this study, 72% of primary prevention patients with
high co-morbidity burden, who could have utilized their device,
never had any appropriate ICD therapy prior to death. However,
when looking at the total population, 11% of primary prevention
© 2016 The Authors
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patients with a high co-morbidity burden had an appropriate ther-
apy during follow-up. Therefore, the question that remains relates
to the definition of ICD benefit. How many patients do we need
to treat in order to justify implantation of a primary prevention
ICD? This is a tough question to answer, and the current study
is unfortunately not equipped to do so. In a recently published
analysis, study populations from several large randomized trials on
primary prevention ICD implantation were combined in order to
assess the benefit of ICD implantation in patients with multiple
co-morbidities.23 The investigators found that, although attenu-
ated, patients with high co-morbidity burden still derived benefit
from ICD implantation. However, certain aspects of this study
are questionable from the current clinical point of view. In the
randomized trials, patients were excluded if they presented with
severe co-morbidities, and therefore the results cannot be uncrit-
ically extrapolated to ‘real-life’ ICD patients. This is also evident
when comparing the 4-year mortality rates in patients with ≥2
co-morbidities between their study, which reported 25% mortal-
ity risk, and our study with a mortality risk of >36%.23 Secondly,
patients in the randomized trials were enrolled in earlier years as
compared with the patients from the DPIR. Major advancements
in medical therapy, on both a pharmacological and interventional
level, have occurred over time, and therefore these patients are not
representative of the current primary prevention ICD population,
making it difficult to extrapolate the results.
Chan et al. investigated the benefit of ICD implantation in
the setting of multiple co-morbidities, and found ICD implan-
tation to be associated with reduced mortality risk irrespec-
tive of co-existing co-morbidities.28 However, with increasing
co-morbidity burden, the benefit of ICD was attenuated and,
even though the interaction P-value was insignificant between the
co-morbidity burden groups, the authors were not able to show
a significant benefit of ICD implantation in patients with multi-
ple co-morbidities. These findings suggest that the benefit of ICD
implantation might be outweighed by the competing mortality risk
associated with these co-morbidities, further stressing the impor-
tance of careful and individual assessment prior to deciding on ICD
implantation.
From previous studies, we know that complication rates are sig-
nificantly higher in patients with multiple or severe co-morbidities,
with reported complication rates up to 21%.23,29,30 Therefore, in
primary prevention patients with high co-morbidity burden, clin-
icians need to exert vigilance and conduct thorough individual
assessments of whether the benefits outweigh the risks of implan-
tation. In secondary prevention patients who have survived a car-
diac arrest, an ICD is generally indicated, as we know that these
patients have a high risk of SCD, and higher utilization of their ICD
device, as compared with primary prevention patients. However,
it is interesting to observe the >50% 4-year mortality risk in sec-
ondary prevention patients with a high co-morbidity burden, and
that 45% of those patients who potentially could have used their
device die without utilizing their device, suggesting a high mortality
for competing causes.
The results from this study pose some interesting questions
regarding utilization of ICD devices in patients with multiple ..
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.. co-morbidities. However, it must be stressed that this is a retro-
spective study without a control population, and therefore we are
not able to draw conclusions regarding the clinical benefit of ICD
implantation in the setting of multiple co-morbidities. Additional
larger studies with a control population are needed to investi-
gate this aspect further. Nevertheless, our results emphasize the
importance of thorough evaluation of the risks and benefits on an
individual level prior to primary prevention ICD implantation in
patients with multiple co-morbidities.
Limitations
The results from the current study are based on prospectively
collected data from registers, and can therefore only be conceived
as hypothesis generating. Furthermore, we cannot eliminate the
possibility of unmeasured confounders. Given the lack of a control
population, we are unable to draw conclusions regarding ICD
efficacy. The risk of underestimation of ICD therapy due to
under-reporting remains, as does the risk of misinterpretation of
appropriate ICD therapies. However, we believe this risk to be very
low. If an ICD therapy occurred, the treating pacemaker technician
or electrophysiologist interrogated the device, and classified the
ICD therapy as appropriate or inappropriate according to the
underlying rhythm. In cases of doubt, an electrophysiologist was
consulted. In addition, we attempted to validate the accuracy of
ICD therapy registration in the DPIR. However, when comparing
the registration in the DPIR with information from patient charts,
we found that in all cases, ICD therapy was better registered
in the DPIR than in patient charts, making proper validation
difficult. Unfortunately device programming, including VT/VF zones
with detection limits, and delays are not reported in the DPIR.
Therefore, we are regrettably not able to provide or take this
information into account.
The Danish National Patient Register’s main function is as an
administrative register, through which all hospital reimbursement
for patient admissions are controlled. The accuracy is vital for
hospital and departmental economics. Co-morbidities were identi-
fied from discharge diagnosis codes in the Danish National Patient
Register (Supplementary material online, Table S1). Previous stud-
ies have reported a high positive predictive value for most diag-
noses utilized in the current study.14 In addition, the definition
of diabetes, heart failure, and COPD incorporated use of rele-
vant medication, in order to ensure the highest possible accuracy.
Therefore, we believe the risk of under- and/or misreporting to be
very low.
Conclusion
In Denmark, patients selected for primary prevention ICD implan-
tation are becoming older with a higher co-morbidity burden,
although the absolute frequency of both primary and secondary
prevention patients with ≥3 co-morbidities remains fairly low
(7%). Increasing co-morbidity burden was not associated with
increasing risk of appropriate ICD therapy in either primary or
secondary prevention patients, although it was associated with
© 2016 The Authors
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increasing mortality risk, with a 4-year mortality rate of >50%
in patients with multiple co-morbidities, irrespective of implant
indication. Furthermore, with increasing co-morbidity burden, a
higher frequency of patients died without ever having utilized
their device, suggesting that the competing risk of non-SCD
is high.
Supplementary Information
Additional Supporting Information may be found in the online
version of this article:
Table S1. ICD codes, procedure codes, and ATC codes for
defining co-morbidities.
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